SubcutaneousAdjunct to in vitro fertilisation procedures and other assisted conception techniques, Anovulatory infertility due to hypothalamic pituitary dysfunctionAdult: 250 mcg as a single dose 24-48 hr after optimal stimulation of follicular growth is achieved.
|
Primary ovarian failure, uncontrolled thyroid or adrenal function; abnormal uterine bleeding; ovarian enlargement or cyst of unknown origin; tumours of the hypothalamus, pituitary gland, and uterus; sex hormone dependent tumours of the reproductive tract and accessory organs; ovarian, uterine, or mammary carcinoma. Post-menopausal women. Pregnancy (including ectopic pregnancy in previous 3 mth).
|
Patient w/ active or history of thromboembolic events, patient undergoing ovarian stimulation or ovulation induction. Lactation.
|
Significant: Ovarian hyperstimulation syndrome (OHSS), multiple births, ovarian enlargement, arterial thromboembolism.
Nervous: Headache, tiredness, mood changes, depression, restlessness.
GI: Nausea, vomiting, abdominal pain and distension.
Genitourinary: Ovarian cysts, ectopic pregnancy.
Others: Pain, burning, inflammation, and brusing at inj site, postoperative pain.
|
|
Monitor oestradiol levels and perform ultrasound to assess follicular development, size, and number. Perform sonographic visualisation to monitor ovulation by determining basal body temp, serum progestin level, and menstruation.
|
May cause false positive result w/ urinary HCG during pregnancy test. May cross-react w/ gonadotropin (esp LH) radioimmunoassay.
|
Description: Choriogonadotropin alfa, an analogue of LH, is a biosynthetic recombinant form of HCG. It binds to LH/HCG receptors of the ovarian granulosa and theca cells in the absence of an endogenous LH surge. This causes stimulation of late ovarian follicular maturation, luteinisation of ovarian follicular granulosa cells, resumption of oocyte meiosis, and initiation of rupture of preovulatory ovarian follicle. Pharmacokinetics: Absorption: Bioavailability: 40%. Time to peak plasma concentration: 12-24 hr. Distribution: Distributed mainly to the gonads. Volume of distribution: 21.4 L. Metabolism: Metabolised mainly in the kidneys. Excretion: Via urine. Elimination half-life: Biphasic: 4 hr (initial); 29 hr (terminal).
|
Store between 2-8°C. Protect from light.
|
|
G03GA08 - choriogonadotropin alfa ; Belongs to the class of gonadotropins. Used as ovulation stimulants.
|
Anon. Chorionic Gonadotrophin (Recombinant). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 23/02/2017. Buckingham R (ed). Chorionic Gonadotrophin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 23/02/2017. Joint Formulary Committee. Choriogonadotropin Alfa (Human Chorionic Gonadotropin). British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 23/02/2017. Ovidrel Injection, Solution (EMD Soreno, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 23/02/2017.
|